Hepatitis B virus reverse transcriptase - Target of current antiviral therapy and future drug development

Antiviral Research

Volumn 123, Issue , 2015, Pages 132-137

  Clark, Daniel N ^a   Hu, Jianming ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Antiviral therapies; HBV; Protein priming; Reverse transcriptase

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS B VIRUS REVERSE TRANSCRIPTASE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL THERAPY; CELL FREE SYSTEM; CELL MATURATION; CHRONIC HEPATITIS B; CLINICAL TRIAL (TOPIC); DNA SYNTHESIS; ENZYME ACTIVITY; ENZYME STRUCTURE; HUMAN; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; DRUG DEVELOPMENT; ENZYMOLOGY; HEPATITIS B VIRUS; ISOLATION AND PURIFICATION; METABOLISM; PROCEDURES; TRENDS;

ANTIVIRAL AGENTS; DRUG DISCOVERY; HEPATITIS B VIRUS; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE;

EID: 84943403551     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2015.09.011     Document Type: Review

References (79)

1. S. Balakrishna Pai, S.H. Liu, Y.L. Zhu, C.K. Chu, and Y.C. Cheng Inhibition of hepatitis B virus by a novel l-nucleoside, 2′-fluoro-5-methyl-beta-l-arabinofuranosyl uracil Antimicrob. Agents Chemother. 40 1996 380 386
2. R. Bartenschlager, and H. Schaller The amino-terminal domain of the hepadnaviral P-gene encodes the terminal protein (genome-linked protein) believed to prime reverse transcription Embo J. 7 1988 4185 4192
3. J. Beck, and M. Nassal A Tyr residue in the reverse transcriptase domain can mimic the protein-priming Tyr residue in the terminal protein domain of a hepadnavirus P protein J. Virol. 85 2011 7742 7753
4. T.M. Block, S. Rawat, and C.L. Brosgart Chronic hepatitis B: a wave of new therapies on the horizon Antiviral Res. 121 2015 69 81
5. R.K. Boregowda, L. Lin, Q. Zhu, F. Tian, and J. Hu Cryptic protein priming sites in two different domains of duck hepatitis B virus reverse transcriptase for initiating DNA synthesis in vitro J. Virol. 85 2011 7754 7765
6. R. Boregowda, C. Adams, and J. Hu TP-RT domain interactions of duck hepatitis B virus reverse transcriptase in cis and in trans during protein-primed initiation of DNA synthesis in vitro J. Virol. 86 2012 6522 6536
7. C.W. Cai, E. Lomonosova, E.A. Moran, X. Cheng, K.B. Patel, F. Bailly, P. Cotelle, M.J. Meyers, and J.E. Tavis Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activity Antiviral Res. 108 2014 48 55
8. J. Chang, and J.T. Guo Treatment of chronic hepatitis B with pattern recognition receptor agonists: current status and potential for a cure Antiviral Res. 121 2015 152 159
9. L. Cheng, F. Li, M.T. Bility, C.M. Murphy, and L. Su Modeling hepatitis B virus infection, immunopathology and therapy in mice Antiviral Res. 121 2015 1 8
10. Y. Chong, and C.K. Chu Understanding the unique mechanism of L-FMAU (clevudine) against hepatitis B virus: molecular dynamics studies Bioorg. Med. Chem. Lett. 12 2002 3459 3462
11. C.K. Chu, T. Ma, K. Shanmuganathan, C. Wang, Y. Xiang, S.B. Pai, G.Q. Yao, J.P. Sommadossi, and Y.C. Cheng Use of 2′-fluoro-5-methyl-beta-l-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus Antimicrob. Agents Chemother. 39 1995 979 981
12. D.N. Clark, and J. Hu Unveiling the roles of HBV polymerase for new antiviral strategies Future Virol. 10 2015 283 295
13. S. Crotty, C. Cameron, and R. Andino Ribavirin's antiviral mechanism of action: lethal mutagenesis? J. Mol. Med. (Berl) 80 2002 86 95
14. G. Cui, X. Xu, and H. Diao Comparative meta-analysis of tenofovir disoproxil fumarate versus emtricitabine and tenofovir disoproxil fumarate as treatments for patients with chronic hepatitis B Sci. Rep. 5 2015 11854
15. K. Das, X. Xiong, H. Yang, C.E. Westland, C.S. Gibbs, S.G. Sarafianos, and E. Arnold Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC) J. Virol. 75 2001 4771 4779
16. K. Das, S.E. Martinez, J.D. Bauman, and E. Arnold HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism Nat. Struct. Mol. Biol. 19 2012 253 259
17. E. De Clercq In search of a selective therapy of viral infections Antiviral Res. 85 2010 19 24
18. E. De Clercq, G. Ferir, S. Kaptein, and J. Neyts Antiviral treatment of chronic hepatitis B virus (HBV) infections Viruses 2 2010 1279 1305
19. H.B. El-Serag Epidemiology of viral hepatitis and hepatocellular carcinoma Gastroenterology 142 1264-1273 2012 e1261
20. W.H. Gerlich, and W.S. Robinson Hepatitis B virus contains protein attached to the 5′ terminus of its complete DNA strand Cell 21 1980 801 809
21. R.G. Gish, B.D. Given, C.L. Lai, S.A. Locarnini, J.Y. Lau, D.L. Lewis, and T. Schluep Chronic hepatitis B: virology, natural history, current management and a glimpse at future opportunities Antiviral Res. 121 2015 47 58
22. R.G. Gish, M.F. Yuen, H.L. Chan, B.D. Given, C.L. Lai, S.A. Locarnini, J.Y. Lau, C.I. Wooddell, T. Schluep, and D.L. Lewis Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent Antiviral Res. 121 2015 97 108
23. S.J. Hadziyannis, D. Vassilopoulos, and E. Hadziyannis Chapter seven - the natural course of chronic hepatitis B virus infection and its management C. Erik De, Advances in Pharmacology 2013 Academic Press 247 291
24. J. Hu, and D. Anselmo In vitro reconstitution of a functional duck hepatitis B virus reverse transcriptase: posttranslational activation by Hsp90 J. Virol. 74 2000 11447 11455
25. J. Hu, and M. Boyer Hepatitis B virus reverse transcriptase and epsilon RNA sequences required for specific interaction in vitro J. Virol. 80 2006 2141 2150
26. J. Hu, and C. Seeger Expression and characterization of hepadnavirus reverse transcriptases Methods Enzymol. 275 1996 195 208
27. J. Hu, and C. Seeger Hsp90 is required for the activity of a hepatitis B virus reverse transcriptase Proc. Natl. Acad. Sci. USA 93 1996 1060 1064
28. Hu, J., Seeger, C., 2015. Hepadnavirus genome replication and persistence. Cold Spring Harbor Perspectives in Medicine 5.
29. J. Hu, D.O. Toft, and C. Seeger Hepadnavirus assembly and reverse transcription require a multi-component chaperone complex which is incorporated into nucleocapsids Embo J. 16 1997 59 68
30. J. Hu, D. Toft, D. Anselmo, and X. Wang In vitro reconstitution of functional hepadnavirus reverse transcriptase with cellular chaperone proteins J. Virol. 76 2002 269 279
31. J. Hu, D. Flores, D. Toft, X. Wang, and D. Nguyen Requirement of heat shock protein 90 for human hepatitis B virus reverse transcriptase function J. Virol. 78 2004 13122 13131
32. Y. Hu, X. Cheng, F. Cao, A. Huang, and J.E. Tavis Beta-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity Antiviral Res. 99 2013 221 229
33. J.H. Jang, J.W. Kim, S.H. Jeong, H.J. Myung, H.S. Kim, Y.S. Park, S.H. Lee, J.H. Hwang, N. Kim, and D.H. Lee Clevudine for chronic hepatitis B: antiviral response, predictors of response, and development of myopathy J. Viral Hepatitis 18 2011 84 90
34. S.A. Jones, and J. Hu Hepatitis B virus reverse transcriptase: diverse functions as classical and emerging targets for antiviral intervention Emerging Microbes Infect. 2 2013 e56
35. S.A. Jones, and J. Hu Protein-primed terminal transferase activity of hepatitis B virus polymerase J. Virol. 87 2013 2563 2576
36. S.A. Jones, R. Boregowda, T.E. Spratt, and J. Hu In vitro epsilon RNA-dependent protein priming activity of human hepatitis B virus polymerase J. Virol. 86 2012 5134 5150
37. S.A. Jones, E. Murakami, W. Delaney, P. Furman, and J. Hu Non-competitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine Antimicrob. Agents Chemother. 57 2013 4181 4189
38. S.A. Jones, D.N. Clark, F. Cao, J.E. Tavis, and J. Hu Comparative analysis of hepatitis B virus polymerase sequences required for viral RNA binding, RNA packaging, and protein priming J. Virol. 88 2014 1564 1572
39. S.B. Kim, I.H. Song, Y.M. Kim, R. Noh, H.Y. Kang, H. Lee, H.Y. Yang, A.N. Kim, H.B. Chae, S.H. Lee, H.S. Kim, T.H. Lee, Y.W. Kang, E.S. Lee, S.H. Kim, B.S. Lee, and H.Y. Lee Long-term treatment outcomes of clevudine in antiviral-naive patients with chronic hepatitis B World J. Gastroenterol. 18 2012 6943 6950
40. B.E. Korba, P.A. Furman, and M.J. Otto Clevudine: a potent inhibitor of hepatitis B virus in vitro and in vivo Expert Rev. Anti Infect Ther. 4 2006 549 561
41. S.Y. Kwon, Y.K. Park, S.H. Ahn, E.S. Cho, W.H. Choe, C.H. Lee, B.K. Kim, S.Y. Ko, H.S. Choi, E.S. Park, G.C. Shin, and K.H. Kim Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients J. Virol. 84 2010 4494 4503
42. R.E. Lanford, L. Notvall, and B. Beames Nucleotide priming and reverse transcriptase activity of hepatitis B virus polymerase expressed in insect cells J. Virol. 69 1995 4431 4439
43. R.E. Lanford, L. Notvall, H. Lee, and B. Beames Transcomplementation of nucleotide priming and reverse transcription between independently expressed TP and RT domains of the hepatitis B virus reverse transcriptase J. Virol. 71 1997 2996 3004
44. H.S. Lee, Y.H. Chung, K. Lee, K.S. Byun, S.W. Paik, J.Y. Han, K. Yoo, H.W. Yoo, J.H. Lee, and B.C. Yoo A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B Hepatology 43 2006 982 988
45. L. Lin, and J. Hu Inhibition of hepadnavirus reverse transcriptase-epsilon RNA interaction by porphyrin compounds J. Virol. 82 2008 2305 2312
46. L. Lin, F. Wan, and J. Hu Functional and structural dynamics of hepadnavirus reverse transcriptase during protein-primed initiation of reverse transcription: effects of metal ions J. Virol. 82 2008 5703 5714
47. L. Menendez-Arias, M. Alvarez, and B. Pacheco Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance Curr. Opin. Virol. 8C 2014 1 9
48. K.L. Molnar-Kimber, J. Summers, J.M. Taylor, and W.S. Mason Protein covalently bound to minus-strand DNA intermediates of duck hepatitis B virus J. Virol. 45 1983 165 172
49. M. Nassal, and A. Rieger A bulged region of the hepatitis B virus RNA encapsidation signal contains the replication origin for discontinuous first-strand DNA synthesis J. Virol. 70 1996 2764 2773
50. C. Niu, H. Bao, T. Tolstykh, H.M. Micolochick Steuer, E. Murakami, B. Korba, and P.A. Furman Evaluation of the in vitro anti-HBV activity of clevudine in combination with other nucleoside/nucleotide inhibitors Antiviral Ther. 15 2010 401 412
51. S.F. Peek, P.J. Cote, J.R. Jacob, I.A. Toshkov, W.E. Hornbuckle, B.H. Baldwin, F.V. Wells, C.K. Chu, J.L. Gerin, B.C. Tennant, and B.E. Korba Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, l-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax) Hepatology 33 2001 254 266
52. S.G. Sarafianos, B. Marchand, K. Das, D.M. Himmel, M.A. Parniak, S.H. Hughes, and E. Arnold Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition J. Mol. Biol. 385 2009 693 713
53. S.J. Scaglione, and A.S. Lok Effectiveness of hepatitis B treatment in clinical practice Gastroenterology 142 1360-1368 2012 e1361
54. C. Seeger, W.S. Mason, and F. Zoulim Hepadnaviruses D.M. Knipe, P.M. Howley, Fields Virology 2007 Lippincott Williams & Wilkins Philadelphia 2977 3029
55. M. Seifer, R.K. Hamatake, R.J. Colonno, and D.N. Standring In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir Antimicrob. Agents Chemother. 42 1998 3200 3208
56. J.I. Seok, D.K. Lee, C.H. Lee, M.S. Park, S.Y. Kim, H.S. Kim, H.Y. Jo, C.H. Lee, and D.S. Kim Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA Hepatology 49 2009 2080 2086
57. A.G. Skillman, K.W. Maurer, D.C. Roe, M.J. Stauber, D. Eargle, T.J. Ewing, A. Muscate, E. Davioud-Charvet, M.V. Medaglia, R.J. Fisher, E. Arnold, H.Q. Gao, R. Buckheit, P.L. Boyer, S.H. Hughes, I.D. Kuntz, and G.L. Kenyon A novel mechanism for inhibition of HIV-1 reverse transcriptase Bioorg. Chem. 30 2002 443 458
58. M. Stahl, J. Beck, and M. Nassal Chaperones activate hepadnavirus reverse transcriptase by transiently exposing a C-proximal region in the terminal protein domain that contributes to epsilon RNA binding J. Virol. 81 2007 13354 13364
59. M. Stahl, M. Retzlaff, M. Nassal, and J. Beck Chaperone activation of the hepadnaviral reverse transcriptase for template RNA binding is established by the Hsp70 and stimulated by the Hsp90 system Nucl. Acids Res. 35 2007 6124 6136
60. K.A. Staschke, and J.M. Colacino Priming of duck hepatitis B virus reverse transcription in vitro: premature termination of primer DNA induced by the 5′-triphosphate of fialuridine J. Virol. 68 1994 8265 8269
61. J. Summers, and W.S. Mason Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate Cell 29 1982 403 415
62. W.Y. Tak, J.M. Yang, B.I. Kim, S.K. Baik, G.J. Cheon, K.S. Byun, D.Y. Kim, and B.C. Yoo A randomized, open-label study comparing low-dose clevudine plus adefovir combination therapy with clevudine monotherapy in naive chronic hepatitis B patients Hepatol. Int. 8 2014 375 381
63. J.E. Tavis, and E. Lomonosova The hepatitis B virus ribonuclease H as a drug target Antiviral Res. 118 2015 132 138
64. J.E. Tavis, X. Cheng, Y. Hu, M. Totten, F. Cao, E. Michailidis, R. Aurora, M.J. Meyers, E.J. Jacobsen, M.A. Parniak, and S.G. Sarafianos The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes PLoS Pathog. 9 2013 e1003125
65. E.P. Tchesnokov, A. Obikhod, R.F. Schinazi, and M. Gotte Delayed chain termination protects the anti-hepatitis B virus drug entecavir from excision by HIV-1 reverse transcriptase J. Biol. Chem. 283 2008 34218 34228
66. X. Wang, and J. Hu Distinct requirement for two stages of protein-primed initiation of reverse transcription in hepadnaviruses J. Virol. 76 2002 5857 5865
67. G.H. Wang, and C. Seeger The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis Cell 71 1992 663 670
68. G.H. Wang, and C. Seeger Novel mechanism for reverse transcription in hepatitis B viruses J. Virol. 67 1993 6507 6512
69. L.Z. Wang, G.L. Kenyon, and K.A. Johnson Novel mechanism of inhibition of HIV-1 reverse transcriptase by a new non-nucleoside analog, KM-1 J. Biol. Chem. 279 2004 38424 38432
70. Y.X. Wang, Y.M. Wen, and M. Nassal Carbonyl J acid derivatives block protein priming of hepadnaviral P protein and DNA-dependent DNA synthesis activity of hepadnaviral nucleocapsids J. Virol. 86 2012 10079 10092
71. M. Weber, V. Bronsema, H. Bartos, A. Bosserhoff, R. Bartenschlager, and H. Schaller Hepadnavirus P protein utilizes a tyrosine residue in the TP domain to prime reverse transcription J. Virol. 68 1994 2994 2999
72. H. Yan, G. Zhong, G. Xu, W. He, Z. Jing, Z. Gao, Y. Huang, Y. Qi, B. Peng, H. Wang, L. Fu, M. Song, P. Chen, W. Gao, B. Ren, Y. Sun, T. Cai, X. Feng, J. Sui, and W. Li Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus eLife 1 2012 1 28
73. H. Yan, Y. Liu, J. Sui, and W. Li NTCP opens the door for hepatitis B virus infection Antiviral Res. 121 2015 24 30
74. G.Q. Yao, S.H. Liu, E. Chou, M. Kukhanova, C.K. Chu, and Y.C. Cheng Inhibition of Epstein-Barr virus replication by a novel l-nucleoside, 2′-fluoro-5-methyl-beta-l-arabinofuranosyluracil Biochem. Pharmacol. 51 1996 941 947
75. M.F. Yuen, S.H. Ahn, K.S. Lee, S.H. Um, M. Cho, S.K. Yoon, J.W. Lee, N.H. Park, Y.O. Kweon, J.H. Sohn, J. Lee, J.A. Kim, C.L. Lai, and K.H. Han Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: results from a multicentre study J. Hepatol. 62 2015 526 532
76. Y. Zhu, M. Curtis, X. Qi, M.D. Miller, and K. Borroto-Esoda Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues Antiviral Chem. Chemother. 19 2009 165 176
77. A. Zlotnick, B. Venkatakrishnan, Z. Tan, E. Lewellyn, W. Turner, and S. Francis Core protein: a pleiotropic keystone in the HBV lifecycle Antiviral Res. 121 2015 82 93
78. F. Zoulim, and S. Locarnini Hepatitis B virus resistance to nucleos(t)ide analogues Gastroenterology 137 1593-1608 2009 e1591 e1592
79. F. Zoulim, and C. Seeger Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase J. Virol. 68 1994 6 13